ArriVent BioPharma, Inc. (AVBP) AI Stock Analysis

• Market Cap: $1.01B
• Dividend Yield: N/A
• Average Volume (3M): 518.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: N/A
• EPS Growth: -75.31%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.84
• Shares Outstanding: 44,201,622
• 10 Day Avg. Volume: 724,660
• 30 Day Avg. Volume: 518,417
• PEG Ratio: -0.07
• Price to Book (P/B): 2.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.82
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -5.61
• 1Y Price Target: $42.33
• Price Target Upside: 85.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -3.81
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $24.50 ▲(7.17% Upside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

The score is mainly constrained by weak financial performance driven by no revenue and accelerating losses/cash burn, partially offset by a low-leverage, well-capitalized balance sheet. Technicals are moderately constructive with price above major moving averages and neutral momentum. Valuation remains pressured due to losses (negative P/E), while the recent positive AACR pipeline update provides a modest support.

Positive Factors

Low leverage / strong balance sheet

Near-zero debt and a materially larger equity base provide durable financial flexibility for a clinical-stage biotech. This reduces refinancing risk, supports multi-phase trial funding, and allows strategic partnering or program prioritization without immediate dependence on dilutive financing.

Robust preclinical data for lead EGFR inhibitor

High-potency activity across EGFR mutations plus demonstrated brain penetration materially de-risks pivotal development for furmonertinib. Such durable pharmacologic advantages support potential late-stage success, differentiation in NSCLC subtypes, and longer-term commercial relevance if Phase 3 trials confirm efficacy.

Differentiated ADC franchise via partnership

A first-in-class dual-target ADC with partner licensing broadens the company's modality footprint beyond small molecules. Superior efficacy and tolerability in preclinical models plus a partner arrangement create durable R&D scale, shared risk, and a higher probability of advancing a commercially competitive ADC program.

Negative Factors

Pre-commercial / no revenue

Being pre-revenue is a structural constraint: operations rely entirely on financing or partnerships rather than product cash flow. Long-term sustainability depends on clinical success and timely funding, making the business vulnerable to trial setbacks and capital market cycles over the next several months.

Rising cash burn and widening losses

Sharply higher cash burn and widening losses materially shorten runway and increase probability of near-term external financing or dilution. This pressures strategic choices, could force reprioritization of programs, and elevates execution risk for multi-phase clinical development plans.

Concentration on few lead programs

Heavy reliance on a small number of lead assets creates binary exposure: clinical or regulatory failure in one program would disproportionately harm prospects. Limited product diversification increases long-term volatility in value creation and makes sustained growth contingent on few trial outcomes.

ArriVent BioPharma, Inc. Business Overview & Revenue Model

Company Description

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

How the Company Makes Money

null

ArriVent BioPharma, Inc. Financial Statement Overview

Summary

Strong balance sheet with near-zero debt and a growing equity base supports financial flexibility, but this is offset by no revenue, widening net losses (~$166.3M in 2025 vs. ~$80.5M in 2024), and sharply higher operating/free cash burn (~-$160.6M in 2025 vs. ~-$70.2M in 2024), increasing funding and dilution risk.

Income Statement

The company reports no revenue across the provided annual periods (2021–2025), consistent with a pre-commercial biotechnology profile. Losses have widened meaningfully in the latest year (net loss of ~$166.3M in 2025 vs. ~$80.5M in 2024), indicating rising operating spend. With negative EBIT/EBITDA in most years and no margin support from revenue, profitability and earnings quality remain weak despite a growing equity base.

Balance Sheet

Balance sheet leverage is very low, with total debt near-zero relative to equity (debt-to-equity effectively ~0% in 2025), which reduces financial risk and provides flexibility. Total assets and stockholders’ equity have increased substantially since 2021, suggesting successful funding and a stronger capital base. The key weakness is persistently negative returns on equity driven by ongoing losses, implying capital is being consumed rather than generating returns.

Cash Flow

Cash burn is significant and trending worse: operating and free cash flow were about -$160.6M in 2025 versus -$70.2M in 2024. While free cash flow has generally tracked net income closely (cash losses roughly matching accounting losses), the overall trajectory points to rising cash needs. The main strength is that cash outflows appear operationally driven rather than debt-funded, but the magnitude of burn heightens funding and dilution risk over time.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-177.53M	-80.49M	-74.59M	0.00	-51.61M
Net Income	-166.31M	-80.49M	-69.33M	-36.91M	-51.61M
Balance Sheet
Total Assets	333.17M	274.94M	163.10M	182.83M	43.04M
Cash, Cash Equivalents and Short-Term Investments	312.82M	218.86M	150.39M	163.37M	37.28M
Total Debt	14.00K	176.00K	317.00K	139.00K	0.00
Total Liabilities	25.95M	17.29M	11.80M	8.37M	1.82M
Stockholders Equity	307.22M	257.65M	151.30M	174.46M	41.22M
Cash Flow
Free Cash Flow	-160.59M	-70.21M	-55.84M	-43.63M	-12.59M
Operating Cash Flow	-160.59M	-70.21M	-55.84M	-43.63M	-12.59M
Investing Cash Flow	-71.23M	-192.47M	0.00	0.00	-40.00M
Financing Cash Flow	203.06M	186.58M	42.86M	169.72M	89.87M

ArriVent BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 22.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Neutral. The current price of 22.86 is below the 20-day moving average (MA) of 23.92, above the 50-day MA of 22.84, and above the 200-day MA of 21.19, indicating a neutral trend. The MACD of 0.22 indicates Positive momentum. The RSI at 45.79 is Neutral, neither overbought nor oversold. The STOCH value of 15.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AVBP.

ArriVent BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IOVA	62 Neutral	$1.59B	-2.50	-54.54%	―	175.62%	19.63%
RLAY	59 Neutral	$1.79B	―	-43.17%	―	-16.50%	33.02%
AVBP	55 Neutral	$1.01B	-4.65	-62.48%	―	―	-75.31%
TSHA	53 Neutral	$1.25B	-16.13	-67.26%	―	-36.36%	-945.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IVA	47 Neutral	$1.25B	-0.42	536.36%	―	-12.52%	-82.84%
QURE	45 Neutral	$940.07M	―	-174.03%	―	-44.90%	11.49%

ArriVent BioPharma, Inc. Corporate Events

ArriVent Highlights Next-Generation Oncology Data at AACR 2026

On March 17, 2026, ArriVent BioPharma announced it would present new preclinical data on its EGFR inhibitor firmonertinib and dual-target MUC16/NaPi2b tetravalent ADC ARR-002 at the 2026 American Association for Cancer Research Annual Meeting in San Diego, running April 17-22. The firmonertinib poster is set to showcase high-resolution structural and functional data supporting its pivotal Phase 3 programs in EGFR exon 20 insertion and PACC mutant non-small cell lung cancer, while ARR-002 data with partner Aarvik Therapeutics will highlight superior anti-tumor activity, enhanced internalization and a favorable tolerability profile in ovarian and endometrial cancer models, reinforcing ArriVent’s push to position its assets as next-generation targeted oncology therapies.

For firmonertinib, preclinical work demonstrated high-potency inhibition across classical and exon 20 insertion EGFR mutations, strong brain penetration and robust anti-tumor activity in multiple in vitro and in vivo models, supporting its role in global late-stage trials. ARR-002, a first-in-class dual-target tetravalent ADC discovered with Aarvik and licensed by ArriVent, showed effective engagement of both MUC16 and NaPi2b, superior in vivo efficacy versus single-target ADCs and signs of a wider therapeutic window in primate studies, suggesting best-in-disease potential in ovarian and endometrial cancers and underlining ArriVent’s broader strategy to build a competitive ADC-based oncology franchise.

The most recent analyst rating on (AVBP) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on ArriVent BioPharma, Inc. stock, see the AVBP Stock Forecast page.